FDA slaps hold on imetelstat studies; Geron whipped
This article was originally published in Scrip
Executive Summary
Investors acted swiftly on 12 March driving shares of Geron down as low as 68.4% after it revealed the FDA had slapped a full clinical hold on the company's Phase II program for its experimental telomerase inhibitor imetelstat (GRN163L) over potential liver injury concerns.
You may also be interested in...
Geron Sees Blockbuster Opportunity For Imetelstat, Eyeing Broader Market Than Reblozyl’s
The company reported positive results from its study in lower-risk myelodysplastic syndrome, where it forecasts a market potentially exceeding 30,000 in US and major European markets and generating up to $1.2bn in sales.
Imetelstat Study Blip Beats Geron’s Shares Down
Shares in Geron dropped by nearly 20% to $2.30 on NASDAQ on Sept. 12 following interim clinical data for its lead product, the anticancer imetelstat, from trials conducted by its partner Janssen.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.